

Role of Bone Biopsy and Deep Tissue Culture for Antibiotic Stewardship in Diabetic Foot Osteomyelitis

¹Department of Medicine, ²Division of Hospital Medicine, ³Division of Hospital Based Medicine, ¹Department of Pediatrics, ⁴Division of Infectious Disease, Northwestern University, Chicago, IL, USA

BACKGROUND

Bone biopsy is the gold standard for diagnosing infectious osteomyelitis (OM), but it is not always done in the setting of diabetic foot infection (DFI), even where resistant organisms are common.

OBJECTIVES

- To describe organisms frequently identified on bone biopsy or deep tissue culture in patients with diabetic foot osteomyelitis (DFO)
- how culture determine data antibiotic use in patients with DFO

METHODS

- Retrospectively reviewed adults admitted with a diabetic foot ulcer (DFU) and selected for those diagnosed with DFO





Figure 1: Flowchart for patient inclusion. We selected for patients diagnosed with DFO and stratified patients by whether a bone biopsy or deep tissue culture was obtained.

impacted



Gram Negative Organisms

Pseudomonas aeruginosa Proteus spp Klebsiella spp Escherichia coli

MDROs

MRSA ESBL

Antibiotics Changed

Narrowed Broadened

Table 1. Bacteria isolated from deep tissue and bone biopsy culture of diabetic foot osteomyelitis and effect on antibiotic therapy

Sara M Hockney, MD¹, Danielle Steker, MD², Ajay Bhasin, MD^{2,3}, Karen M Krueger, MD⁴, Janna Williams, MD⁴, Shannon Galvin, MD⁴

nts	(n=47) Percent	t
	43	91.5%
	32	68.1%
	13	27.7%
	8	17.0%
	14	29.8%
	12	25.5%
	17	36.2%
	3	6.4%
	6	12.8%
	5	10.6%
	3	6.4%
	7	14.9%
	5	10.6%
	2	4.3%
	41	87.2%
	29	61.7%
	4	8.5%




Figure 3: Culture data allowed for decreased rates of MRSA and **Pseudomonas coverage**. Culture data allowed for discontinuation of MRSA coverage (vancomycin, daptomycin, linezolid, doxycycline, and trimethoprim-sulfamethoxazole) in 47% of patients and pseudomonal coverage (aztreonam, cefepime, meropenem, and piperacillintazobactam) in 49% of patients.

CONCLUSIONS

In patients with DFO, bone biopsy and deep tissue culture was infrequently obtained but resulted in targeted therapy changes in most patients. Culture data usually allowed for narrowing of antibiotics but revealed inadequate empiric coverage in a subset of patients.





Northwestern Medicine[®]